IP Library Granted Patent US 9,532,973
Granted Patent B2
US 9,532,973 · App. 14/643,442 · Granted Jan 3, 2017

Use of coumarin derivatives for the preparation of drugs for treating skin diseases

Inventors: Michele Reboud-Ravaux (Paris, FR); Chahrazade Yerroum-El Amri (Ermont, FR); Xiao Tan (Villejuif, FR); Lixian Qin (Paris, FR); Maurice Pagano (Limours, FR); Alain Hovnanian (Vincennes, FR); Laetitia Furio (Montrouge, FR); Bernard Pirotte (Oupeye, BE)
Assignees: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); UNIVERSITE DE LIEGE
A61K31/37A61K31/4433A61K31/4725C07D311/12C07D311/14C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,532,973
App. No.
14/643,442
Granted
Jan 3, 2017
Kind
B2
Abstract

A compound of formula (I-1) wherein n equals 0 or 1, Z represents O or S, R1 represents one group chosen among the group consisting of hydrogen, C1-C7 alkyl, substituted, or not, by a halogen, a hydroxyl or a —O—R12 group, wherein R12 is a C1-C7 alkyl, a group —CH 2 —O—CO—R5 wherein R5 is chosen among a hydrogen atom and a C1-C7 alkyl, substituted or not by at least one halogen, a group —O—R13, wherein R13 is chosen among hydrogen and a C1-C7 alkyl, an amine or a —CH 2 -amine, R′1 represents a group chosen among hydrogen and —O—R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for the treatment of pathologies involving excess activity of at least one member of the kallikrein family.

Claims (6)

1. A method for the treatment of a pathology involving an excess of activity of at least one member of the kallikrein family, comprising administering to a patient in need thereof a composition comprising an effective amount of a compound selected from the group consisting of:

said at least one member of the kallikrein family being selected from the group consisting of kallikrein-5 and kallikrein-7;

said pathology being selected from the group consisting of Netherton syndrome, psoriasis, atopic eczema and allergic contact dermatitis.

2. The method according to claim 1 , wherein said compound is

3. The method according to claim 1 , wherein said compound is:

4. The method according to claim 1 , wherein said pathology is Netherton syndrome.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2015
From: REBOUD-RAVAUX, MICHELE; YERROUM-EL AMRI, CHAHRAZADE; TAN, XIAO; QIN, LIXIAN; HADOT (LEGAL REP. OF MAURICE PAGANO - DECEASED), KARLA; PAGANO (LEGAL REP. OF MAURICE PAGANO - DECEASED), ADRIEN; HOVNANIAN, ALAIN; FURIO, LAETITIA; PIROTTE, BERNARD
To: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); UNIVERSITE DE LIEGE
Reel/Frame 035151/0237 →
Priority Claims (1)
EP 11305931 · Jul 15, 2011 · regional
Continuity (3)
Division 14155633 · Jan 15, 2014
Continuation In Part PCTEP2012063851 · Jul 13, 2012
Related Publication 20150182499A1 · Jul 2, 2015